Powered by: Motilal Oswal

News

Zydus Lifesciences gains on getting USFDA`s approval for Lidocaine and Prilocaine cream Zydus Lifesciences is currently trading at Rs. 987.20, up by 8.10 points or 0.83% from its previous closing of Rs. 979.10 on the BSE. The scrip opened at Rs. 969.00 and has touched a high and low of Rs. 988.70 and Rs. 965.90 respectively. So far 14140 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 648.05 on 21-Dec-2023. Last one week high and low of the scrip stoo...
Zydus Lifesciences gains on getting USFDA`s approval for Lidocaine and Prilocaine cream
Zydus Lifesciences gains on getting USFDA`s approval for Lidocaine and Prilocaine cream
Source: Accord Fintech
2024-12-19 03:08:08 pm
Buy Zydus LifeSciences Ltd For Target Rs.1,010 By Motilal Oswal Financial Services Ltd The US and international markets drive earnings Broad-based efforts to improve growth prospects across focus markets * Zydus LifeSciences (ZYDUSLIF) delivered better-than-expected operational performance for the quarter. While its revenue grew at a lower rate of 19% YoY (vs. est. of 25%), improved traction in the US and other international markets resulted in better-than-expected margins for 2QFY25. * We raise our earnings by 3%/4%/3% for FY25E/FY26E/FY27E to factor in: 1) superior ...
Buy Zydus LifeSciences Ltd For Target Rs.1,010 By Motilal Oswal Financial Services Ltd
Buy Zydus LifeSciences Ltd For Target Rs.1,010 By Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services
2024-12-02 04:12:57 pm
India`s Zydus Life posts Q2 profit rise on steady US demand Indian drugmaker Zydus Lifesciences reported a 14% rise in second-quarter profit on Tuesday, helped by strong demand for generic drugs in its key United States and Indian markets. The company's consolidated net profit rose to 9.11 billion rupees ($107.93 million), in line with analysts' average estimate of 9.13 billion rupees, as per data compiled by LSEG. Its total revenue climbed 20% to 52.37 billion rupees, boosted by a nearly 30% growth in its U.S. market and a 10% climb in ...
India`s Zydus Life posts Q2 profit rise on steady US demand
India`s Zydus Life posts Q2 profit rise on steady US demand
Source: Reuters
2024-11-12 02:06:25 pm
Zydus Lifesciences jumps on getting in principle acceptability from WHO for ZyVac TCV Zydus Lifesciences is currently trading at Rs. 1015.00, up by 26.80 points or 2.71% from its previous closing of Rs. 988.20 on the BSE. The scrip opened at Rs. 981.05 and has touched a high and low of Rs. 1016.35 and Rs. 981.05 respectively. So far 33456 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 567.85 on 26-Oct-2023. Last one week high and low of the scrip s...
Zydus Lifesciences jumps on getting in principle acceptability from WHO for ZyVac TCV
Zydus Lifesciences jumps on getting in principle acceptability from WHO for ZyVac TCV
Source: Accord Fintech
2024-10-23 02:55:37 pm
Zydus Lifesciences inches up on getting USFDA`s approval for Fludrocortisone Acetate Tablets Zydus Lifesciences is currently trading at Rs. 1022.85, up by 1.95 points or 0.19% from its previous closing of Rs. 1020.90 on the BSE. The scrip opened at Rs. 1025.05 and has touched a high and low of Rs. 1028.00 and Rs. 1013.95 respectively. So far 4727 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 567.85 on 26-Oct-2023. Last one week high and low of the scrip ...
Zydus Lifesciences inches up on getting USFDA`s approval for Fludrocortisone Acetate Tablets
Zydus Lifesciences inches up on getting USFDA`s approval for Fludrocortisone Acetate Tablets
Source: Accord Fintech
2024-10-18 09:58:30 am
Zydus Lifesciences gains on getting USFDA`s final approval for Paliperidone Extended-Release Tablets Zydus Lifesciences is currently trading at Rs. 1062.75, up by 5.75 points or 0.54% from its previous closing of Rs. 1057.00 on the BSE. The scrip opened at Rs. 1062.00 and has touched a high and low of Rs. 1064.15 and Rs. 1052.00 respectively. So far 67192 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 567.85 on 26-Oct-2023. Last one week high and low of the scrip...
Zydus Lifesciences gains on getting USFDA`s final approval for Paliperidone Extended-Release Tablets
Zydus Lifesciences gains on getting USFDA`s final approval for Paliperidone Extended-Release Tablets
Source: Accord Fintech
2024-10-11 12:50:42 pm
Zydus Lifesciences trades higher on the BSE Zydus Lifesciences is currently trading at Rs. 1080.90, up by 12.55 points or 1.17% from its previous closing of Rs. 1068.35 on the BSE. The scrip opened at Rs. 1076.95 and has touched a high and low of Rs. 1081.30 and Rs. 1063.00 respectively. So far 10411 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 567.85 on 26-Oct-2023. Last one week high and low of the scri...
Zydus Lifesciences trades higher on the BSE
Zydus Lifesciences trades higher on the BSE
Source: Accord Fintech
2024-10-01 02:26:10 pm
Zydus Lifesciences gains on getting USFDA’s final approval for Scopolamine Transdermal System Zydus Lifesciences gains on getting USFDA’s final approval for Scopolamine Transdermal System Aug-30-2024   14:08 Hrs IST Zydus Lifesciences is currently trading at Rs. 1145.55, up by 13.30 points or 1.17% from its previous closing of Rs. 1132.25 on the BSE. The scrip opened at Rs. 1140.00 and has touched a high and low of Rs. 1159.00 and Rs. 1128.95 respectively. So far 155881 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 h...
Zydus Lifesciences gains on getting USFDA’s final approval for Scopolamine Transdermal System
Zydus Lifesciences gains on getting USFDA’s final approval for Scopolamine Transdermal System
Source: Accord Fintech
2024-08-30 02:28:43 pm
Zydus Lifesciences surges on getting final nod to market Amantadine extended-release capsules Zydus Lifesciences is currently trading at Rs. 1134.20, up by 20.35 points or 1.83% from its previous closing of Rs. 1113.85 on the BSE. The scrip opened at Rs. 1147.05 and has touched a high and low of Rs. 1156.45 and Rs. 1128.05 respectively. So far 38036 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 567.85 on 26-Oct-2023. Last one week high and low of the scri...
Zydus Lifesciences surges on getting final nod to market Amantadine extended-release capsules
Zydus Lifesciences surges on getting final nod to market Amantadine extended-release capsules
Source: Accord Fintech
2024-08-28 09:46:10 am
India's Zydus Lifesciences Q1 profit beats estimates on strong US demand Indian drugmaker Zydus Lifesciences reported a bigger-than-expected first-quarter profit on Friday, driven by strong demand for its generic respiratory drugs in its key market of North America. The company's consolidated net profit jumped nearly 31% year-on-year to 14.2 billion rupees ($169.2 million) in the quarter ended June 30, beat analysts' average estimate of 12.34 billion rupees, per LSEG data. KEY CONTEXT Indian generic drugmakers earn a major chunk of their revenue f...
India's Zydus Lifesciences Q1 profit beats estimates on strong US demand
India's Zydus Lifesciences Q1 profit beats estimates on strong US demand
Source: Reuters
2024-08-09 01:47:48 pm
Zydus Lifesciences soars on getting nod to market Bhava to treat various cancers Zydus Lifesciences is currently trading at Rs. 1163.60, up by 19.00 points or 1.66% from its previous closing of Rs. 1144.60 on the BSE. The scrip opened at Rs. 1139.80 and has touched a high and low of Rs. 1165.45 and Rs. 1122.00 respectively. So far 8396 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1203.20 on 11-Jul-2024 and a 52 week low of Rs. 564.05 on 25-Jul-2023. Last one week high and low of the scrip...
Zydus Lifesciences soars on getting nod to market Bhava to treat various cancers
Zydus Lifesciences soars on getting nod to market Bhava to treat various cancers
Source: Accord Fintech
2024-07-22 10:23:36 am
Zydus Lifesciences falls after USFDA classifies its`Jarod unit as `official action indicated` Zydus Lifesciences is currently trading at Rs. 1160.15, down by 25.15 points or 2.12% from its previous closing of Rs. 1185.30 on the BSE. The scrip opened at Rs. 1165.00 and has touched a high and low of Rs. 1168.75 and Rs. 1151.00 respectively. So far 89918 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1203.20 on 11-Jul-2024 and a 52 week low of Rs. 564.05 on 25-Jul-2023. Last one week high and low of the sc...
Zydus Lifesciences falls after USFDA classifies its`Jarod unit as `official action indicated`
Zydus Lifesciences falls after USFDA classifies its`Jarod unit as `official action indicated`
Source: Accord Fintech
2024-07-19 12:28:26 pm
Zydus Lifesciences inches up on getting USFDA`s final approval for Sacubitril and Valsartan Tablets Zydus Lifesciences is currently trading at Rs. 1181.15, up by 0.75 points or 0.06% from its previous closing of Rs. 1180.40 on the BSE. The scrip opened at Rs. 1199.45 and has touched a high and low of Rs. 1203.20 and Rs. 1176.35 respectively. So far 26907 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1,203.20 on 11-Jul-2024 and a 52 week low of Rs. 564.05 on 25-Jul-2023. Last one week high and low of the scri...
Zydus Lifesciences inches up on getting USFDA`s final approval for Sacubitril and Valsartan Tablets
Zydus Lifesciences inches up on getting USFDA`s final approval for Sacubitril and Valsartan Tablets
Source: Accord Fintech
2024-07-11 11:38:54 am
Neutral Zydus LifeSciences Ltd. For Target Rs. 1,045 By Motilal Oswal Financial Services Niche products, superior execution boost earnings Levers in place to improve business prospects over next 2-3 years * Zydus Life (ZYDUS) delivered a better-than-expected 4QFY24 performance, driven by increased off-take in the US/EU/API segments. ZYDUS saw better growth than the industry in the domestic formulation (DF) market. It ended FY24 on a strong note with 13%/41%/65% YoY growth in revenue/EBITDA/PAT. * We raise our earnings estimates by 12%/14% for FY25/FY26 to factor in a) ni...
Neutral Zydus LifeSciences Ltd. For Target Rs. 1,045 By Motilal Oswal Financial Services
Neutral Zydus LifeSciences Ltd. For Target Rs. 1,045 By Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services
2024-07-01 01:59:39 pm
Buy Zydus Lifesciences Ltd.For Target Rs. 1,321 - Elara Capital Guidance smashes the sceptics Convincing beat in Q4 Zydus Lifesciences’ (ZYDUSLIF IN) Q4FY24 revenue and EBITDA beat our estimates by 3% each and PAT by 8%. EBITDA and PAT were 13% and 24% better than consensus estimates. Contribution from gRevlimid in the US helped the upside, though with strong support from all other businesses. We estimate ~USD 80mn of gRevlimid sales in the quarter. Exceptionally strong guidance More surprising than Q4 show was the exceptionally strong ...
Buy Zydus Lifesciences Ltd.For Target Rs. 1,321 - Elara Capital
Buy Zydus Lifesciences Ltd.For Target Rs. 1,321 - Elara Capital
Source: Elara Capital
2024-06-15 11:30:03 am
Zydus Lifesciences jumps on getting USFDA`s tentative nod for Azilsartan Medoxomil and Chlorthalidone Tablets Zydus Lifesciences is currently trading at Rs. 1103.45, up by 13.15 points or 1.21% from its previous closing of Rs. 1090.30 on the BSE. The scrip opened at Rs. 1095.20 and has touched a high and low of Rs. 1109.70 and Rs. 1093.80 respectively. So far 112109 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1171.95 on 21-May-2024 and a 52 week low of Rs. 533.10 on 15-Jun-2023. Last one week high and low of the scr...
Zydus Lifesciences jumps on getting USFDA`s tentative nod for Azilsartan Medoxomil and Chlorthalidone Tablets
Zydus Lifesciences jumps on getting USFDA`s tentative nod for Azilsartan Medoxomil and Chlorthalidone Tablets
Source: Accord Fintech
2024-06-14 03:53:41 pm
Zydus Lifesciences surges as its arm signs exclusive licensing, supply agreement with MSN Laboratories Zydus Lifesciences is currently trading at Rs. 1024.20, up by 15.50 points or 1.54% from its previous closing of Rs. 1008.70 on the BSE. The scrip opened at Rs. 1016.05 and has touched a high and low of Rs. 1026.05 and Rs. 1011.00 respectively. So far 5360 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1033.15 on 07-May-2024 and a 52 week low of Rs. 482.55 on 22-May-2023. Last one week high and low of the scrip...
Zydus Lifesciences surges as its arm signs exclusive licensing, supply agreement with MSN Laboratories
Zydus Lifesciences surges as its arm signs exclusive licensing, supply agreement with MSN Laboratories
Source: Accord Fintech
2024-05-17 10:46:54 am
Zydus Lifesciences edges higher on getting nod for new drug application of Desidustat Tablets Zydus Lifesciences is currently trading at Rs. 960.45, up by 1.00 points or 0.10% from its previous closing of Rs. 959.45 on the BSE. The scrip opened at Rs. 960.55 and has touched a high and low of Rs. 965.00 and Rs. 945.05 respectively. So far 26965 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1031.30 on 01-Apr-2024 and a 52 week low of Rs. 482.55 on 22-May-2023. Last one week high and low of the scrip stoo...
Zydus Lifesciences edges higher on getting nod for new drug application of Desidustat Tablets
Zydus Lifesciences edges higher on getting nod for new drug application of Desidustat Tablets
Source: Accord Fintech
2024-04-23 04:25:19 pm
Zydus Lifesciences surges on launching Mirabegron Extended-Release tablets in US market Zydus Lifesciences is currently trading at Rs. 940.00, up by 17.80 points or 1.93% from its previous closing of Rs. 922.20 on the BSE. The scrip opened at Rs. 935.15 and has touched a high and low of Rs. 950.30 and Rs. 935.15 respectively. So far 969 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1031.30 on 01-Apr-2024 and a 52 week low of Rs. 482.55 on 22-May-2023. Last one week high and low of the scrip stood...
Zydus Lifesciences surges on launching Mirabegron Extended-Release tablets in US market
Zydus Lifesciences surges on launching Mirabegron Extended-Release tablets in US market
Source: Accord Fintech
2024-04-22 09:39:21 am
Zydus Lifesciences climbs on getting USFDA`s tentative approval for Letermovir Tablets Zydus Lifesciences is currently trading at Rs. 1020.35, up by 20.85 points or 2.09% from its previous closing of Rs. 999.50 on the BSE. The scrip opened at Rs. 1009.70 and has touched a high and low of Rs. 1028.45 and Rs. 995.15 respectively. So far 62307 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1028.45 on 26-Mar-2024 and a 52 week low of Rs. 471.10 on 27-Mar-2023. Last one week high and low of the scrip ...
Zydus Lifesciences climbs on getting USFDA`s tentative approval for Letermovir Tablets
Zydus Lifesciences climbs on getting USFDA`s tentative approval for Letermovir Tablets
Source: Accord Fintech
2024-03-26 03:39:03 pm
Zydus Lifesciences jumps on getting USFDA`s final approval for Chlorpromazine Hydrochloride Injection, Single-Dose Vials Zydus Lifesciences is currently trading at Rs. 990.40, up by 21.70 points or 2.24% from its previous closing of Rs. 968.70 on the BSE. The scrip opened at Rs. 969.05 and has touched a high and low of Rs. 999.70 and Rs. 961.85 respectively. So far 35265 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1015.70 on 11-Mar-2024 and a 52 week low of Rs. 463.20 on 14-Mar-2023. Last one week high and low of the scrip sto...
Zydus Lifesciences jumps on getting USFDA`s final approval for Chlorpromazine Hydrochloride Injection, Single-Dose Vials
Zydus Lifesciences jumps on getting USFDA`s final approval for Chlorpromazine Hydrochloride Injection, Single-Dose Vials
Source: Accord Fintech
2024-03-14 02:33:48 pm
Zydus Lifesciences trades higher on the BSE Zydus Lifesciences is currently trading at Rs. 1007.05, up by 30.25 points or 3.10% from its previous closing of Rs. 976.80 on the BSE. The scrip opened at Rs. 986.60 and has touched a high and low of Rs. 1015.70 and Rs. 980.00 respectively. So far 44133 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1015.70 on 11-Mar-2024 and a 52 week low of Rs. 461.50 on 13-Mar-2023. Last one week high and low of the scrip s...
Zydus Lifesciences trades higher on the BSE
Zydus Lifesciences trades higher on the BSE
Source: Accord Fintech
2024-03-11 11:22:30 am
Accumulate Zydus Lifesciences Ltd For Target Rs. 855 - Prabhudas Lilladher Pvt. Ltd. Zydus Lifesciences (ZYDUSLIF) Q3 EBITDA of Rs10.8bn (up 27% YoY) was 5% above our estimate aided by higher GMs and domestic formulation. We believe that company’s steady domestic franchise, strong balance sheet and potential new launches in US will help negate pricing pressure and likely competition in some key products like gAsacol. Moreover, ZYDUSLIF is also working on robust pipeline of complex products including injectables, transdermals, NCE, biosimilars and vac...
Accumulate Zydus Lifesciences Ltd For Target Rs. 855 - Prabhudas Lilladher Pvt. Ltd.
Accumulate Zydus Lifesciences Ltd For Target Rs. 855 - Prabhudas Lilladher Pvt. Ltd.
Source: Prabhudas Lilladher Pvt. Ltd.
2024-03-08 09:48:25 am
Zydus Lifesciences trades higher on getting post application action letter for cGMP, PAI at Ahmedabad facility Zydus Lifesciences is currently trading at Rs. 974.95, up by 12.90 points or 1.34% from its previous closing of Rs. 962.05 on the BSE. The scrip opened at Rs. 962.00 and has touched a high and low of Rs. 982.10 and Rs. 958.55 respectively. So far 94414 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 964.50 on 06-Mar-2024 and a 52 week low of Rs. 461.50 on 13-Mar-2023. Last one week high and low of the scrip stoo...
Zydus Lifesciences trades higher on getting post application action letter for cGMP, PAI at Ahmedabad facility
Zydus Lifesciences trades higher on getting post application action letter for cGMP, PAI at Ahmedabad facility
Source: Accord Fintech
2024-03-07 02:53:14 pm
Exclusive-Eli Lilly could launch obesity drug in India next year, CEO says U.S. drugmaker Eli Lilly expects to launch Mounjaro, its blockbuster diabetes drug and wildly popular obesity treatment, in India as early as next year after it clears an ongoing regulatory review, CEO David Ricks told Reuters on Wednesday. The market opportunity is huge in the world's most populous country, which has high obesity rates, especially among women, and the second-highest number of people with type-2 diabetes globally. Indian drugmakers are making their own versions of such...
Exclusive-Eli Lilly could launch obesity drug in India next year, CEO says
Exclusive-Eli Lilly could launch obesity drug in India next year, CEO says
Source: Reuters
2024-02-28 05:09:26 pm
Zydus Lifesciences gains on getting WHO prequalification approval for Miltefosine formulation, API Zydus Lifesciences is currently trading at Rs. 930.90, up by 8.80 points or 0.95% from its previous closing of Rs. 922.10 on the BSE. The scrip opened at Rs. 934.55 and has touched a high and low of Rs. 934.55 and Rs. 922.85 respectively. So far 7505 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 937.00 on 23-Feb-2024 and a 52 week low of Rs. 452.20 on 27-Feb-2023. Last one week high and low of the scrip stood ...
Zydus Lifesciences gains on getting WHO prequalification approval for Miltefosine formulation, API
Zydus Lifesciences gains on getting WHO prequalification approval for Miltefosine formulation, API
Source: Accord Fintech
2024-02-26 10:37:48 am
Zydus Lifesciences gains on incorporating wholly owned subsidiary in UAE Zydus Lifesciences is currently trading at Rs. 910.90, up by 6.10 points or 0.67% from its previous closing of Rs. 904.80 on the BSE. The scrip opened at Rs. 892.60 and has touched a high and low of Rs. 911.75 and Rs. 892.60 respectively. So far 17555 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 916.60 on 23-Feb-2024 and a 52 week low of Rs. 452.20 on 27-Feb-2023. Last one week high and low of the scrip stood...
Zydus Lifesciences gains on incorporating wholly owned subsidiary in UAE
Zydus Lifesciences gains on incorporating wholly owned subsidiary in UAE
Source: Accord Fintech
2024-02-23 10:41:30 am
Accumulate Zydus Lifesciences Ltd Target Rs. 855 - Prabhudas Liladhar Ltd Zydus Lifesciences (ZYDUSLIF) Q3 EBITDA of Rs10.8bn (up 27% YoY) was 5% above our estimate aided by higher GMs and domestic formulation. We believe that company’s steady domestic franchise, strong balance sheet and potential new launches in US will help negate pricing pressure and likely competition in some key products like gAsacol. Moreover, ZYDUSLIF is also working on robust pipeline of complex products including injectables, transdermals, NCE, biosimilars and vac...
Accumulate Zydus Lifesciences Ltd Target Rs. 855 - Prabhudas Liladhar Ltd
Accumulate Zydus Lifesciences Ltd Target Rs. 855 - Prabhudas Liladhar Ltd
Source: Prabhudas Liladhar
2024-02-20 12:06:53 pm
Buy Zydus LifeSciences For Target Rs.820 - Motilal Oswal Financial Services Ltd India/US/EM drives earnings Work in progress for innovative pipeline * Zydus Life sciences (ZYDUSLIF) delivered better-than-expected performance for 3QFY24. ZYDUSLIF exhibited superior execution in the domestic formulation (DF) and emerging markets; however, this was partly offset by a subdued performance in the API segment for the quarter. * We raise our earnings estimate by 6%/7% for FY24/FY25 to factor in a) the extended limited competition for g-Asacol, b) DF growth surpassing in...
Buy Zydus LifeSciences For Target Rs.820 - Motilal Oswal Financial Services Ltd
Buy Zydus LifeSciences For Target Rs.820 - Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services Ltd
2024-02-12 12:57:04 pm
India`s Zydus Lifesciences beats Q3 profit estimates; approves shares buyback Indian generic drugmaker Zydus Lifesciences reported a bigger-than-expected rise in third-quarter profit on Friday, driven by strong sales in its domestic and overseas markets. Consolidated net profit for the company rose 27% to 7.90 billion rupees (about $95 million) for the three months ended Dec. 31, beating analysts' average estimate of 6.83 billion rupees, as per LSEG data. Separately, Zydus Lifesciences approved the buyback of shares worth six billion rupees via tender offer r...
India`s Zydus Lifesciences beats Q3 profit estimates; approves shares buyback
India`s Zydus Lifesciences beats Q3 profit estimates; approves shares buyback
Source: Reuters
2024-02-09 02:38:55 pm
Zydus Lifesciences rises on getting final nods for Dexamethasone Tablets Zydus Lifesciences is currently trading at Rs. 808.40, up by 6.55 points or 0.82% from its previous closing of Rs. 801.85 on the BSE. The scrip opened at Rs. 805.00 and has touched a high and low of Rs. 809.85 and Rs. 802.00 respectively. So far 2090 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 809.85 on 09-Feb-2024 and a 52 week low of Rs. 452.20 on 27-Feb-2023. Last one week high and low of the scrip stood ...
Zydus Lifesciences rises on getting final nods for Dexamethasone Tablets
Zydus Lifesciences rises on getting final nods for Dexamethasone Tablets
Source: Accord Fintech
2024-02-09 09:55:55 am
Zydus Lifesciences surges on launching Relugolix Zydus Lifesciences is currently trading at Rs. 757.00, up by 8.15 points or 1.09% from its previous closing of Rs. 748.85 on the BSE. The scrip opened at Rs. 749.15 and has touched a high and low of Rs. 760.00 and Rs. 749.15 respectively. So far 20828 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 760.00 on 30-Jan-2024 and a 52 week low of Rs. 425.05 on 03-Feb-2023. Last one week high and low of the scrip stood...
Zydus Lifesciences surges on launching Relugolix
Zydus Lifesciences surges on launching Relugolix
Source: Accord Fintech
2024-01-30 12:25:42 pm
Zydus Lifesciences gains as its arm enters into licensing and supply agreement with Synthon BV Zydus Lifesciences is currently trading at Rs. 710.85, up by 2.00 points or 0.28% from its previous closing of Rs. 708.85 on the BSE. The scrip opened at Rs. 711.05 and has touched a high and low of Rs. 726.65 and Rs. 710.70 respectively. So far 11645 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 726.65 on 19-Jan-2024 and a 52 week low of Rs. 421.50 on 27-Jan-2023. Last one week high and low of the scrip stood...
Zydus Lifesciences gains as its arm enters into licensing and supply agreement with Synthon BV
Zydus Lifesciences gains as its arm enters into licensing and supply agreement with Synthon BV
Source: Accord Fintech
2024-01-19 10:04:15 am
Zydus Lifesciences moves higher on getting USFDA`s nod to initiate Phase II clinical study of`ZYIL1` in patients Zydus Lifesciences is currently trading at Rs. 674.90, up by 28.70 points or 4.44% from its previous closing of Rs. 646.20 on the BSE. The scrip opened at Rs. 650.40 and has touched a high and low of Rs. 677.25 and Rs. 650.40 respectively. So far 164482 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 677.25 on 18-Dec-2023 and a 52 week low of Rs. 401.05 on 19-Dec-2022. Last one week high and low of the scrip sto...
Zydus Lifesciences moves higher on getting USFDA`s nod to initiate Phase II clinical study of`ZYIL1` in patients
Zydus Lifesciences moves higher on getting USFDA`s nod to initiate Phase II clinical study of`ZYIL1` in patients
Source: Accord Fintech
2023-12-18 10:30:48 am
Zydus Lifesciences rises on getting USFDA`s final approval for Darunavir Tablets 600 mg, 800 mg Zydus Lifesciences is currently trading at Rs. 648.90, up by 5.40 points or 0.84% from its previous closing of Rs. 643.50 on the BSE. The scrip opened at Rs. 651.05 and has touched a high and low of Rs. 651.05 and Rs. 645.95 respectively. So far 1340 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 401.05 on 19-Dec-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences rises on getting USFDA`s final approval for Darunavir Tablets 600 mg, 800 mg
Zydus Lifesciences rises on getting USFDA`s final approval for Darunavir Tablets 600 mg, 800 mg
Source: Accord Fintech
2023-12-15 09:42:00 am
Zydus Lifesciences surges on getting USFDA`s final approval for Methylene Blue Injection Zydus Lifesciences is currently trading at Rs. 636.30, up by 2.80 points or 0.44% from its previous closing of Rs. 633.50 on the BSE. The scrip opened at Rs. 636.00 and has touched a high and low of Rs. 644.15 and Rs. 634.75 respectively. So far 13450 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 401.05 on 19-Dec-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences surges on getting USFDA`s final approval for Methylene Blue Injection
Zydus Lifesciences surges on getting USFDA`s final approval for Methylene Blue Injection
Source: Accord Fintech
2023-12-06 03:36:40 pm
Zydus Lifesciences gains on getting USFDA`s final approval for Ivabradine Tablets Zydus Lifesciences is currently trading at Rs. 639.65, up by 1.80 points or 0.28% from its previous closing of Rs. 637.85 on the BSE. The scrip opened at Rs. 640.00 and has touched a high and low of Rs. 648.70 and Rs. 639.65 respectively. So far 26027 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 401.05 on 19-Dec-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences gains on getting USFDA`s final approval for Ivabradine Tablets
Zydus Lifesciences gains on getting USFDA`s final approval for Ivabradine Tablets
Source: Accord Fintech
2023-12-01 02:02:26 pm
Buy Zydus Lifesciences Ltd For Target Rs.720 - JM Financial Services ZYDUSLIF reported a robust EBITDAM of 26.2% despite no gRevlimid contribution. The company’s near-term launch pipeline remains attractive with a few niche launches, two transdermal launches, one REMS, gVascepa (3Q) and the Sitagliptin franchise. It plans to launch ~30 products annually with one exclusivity product in each of FY25/26/27. The LiqMeds acquisition is attractive as it provides access to specialty assets in UK/ US and is also EPS accretive. These initiatives will cumulatively...
Buy Zydus Lifesciences Ltd For Target Rs.720 - JM Financial Services
Buy Zydus Lifesciences Ltd For Target Rs.720 - JM Financial Services
Source: JM Financial Institutional Securities Ltd
2023-11-25 02:47:46 pm
India`s Zydus Q2 profit jumps on strong domestic, US demand Indian generic drugmaker Zydus Lifesciences Ltd reported a better-than-expected 53.3% jump in quarterly profit on Tuesday, led by the strong sales in the domestic market and the United States. Consolidated net profit was 8.01 billion rupees ($96.2 million) in the quarter ended Sept 30, compared with 5.23 billion rupees a year earlier. Analysts, on an average, expected a profit of 7.58 billion rupees, per LSEG data. Total revenue from operations rose 9.1% to 43.69 billion rupees, boosted...
India`s Zydus Q2 profit jumps on strong domestic, US demand
India`s Zydus Q2 profit jumps on strong domestic, US demand
Source: Reuters
2023-11-07 02:07:23 pm
Zydus Lifesciences moves up on getting USFDA`s approval for ZITUVIMET Zydus Lifesciences is currently trading at Rs. 589.45, up by 4.85 points or 0.83% from its previous closing of Rs. 584.60 on the BSE. The scrip opened at Rs. 585.05 and has touched a high and low of Rs. 591.05 and Rs. 585.05 respectively. So far 562 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 390.10 on 22-Nov-2022. Last one week high and low of the scrip stood a...
Zydus Lifesciences moves up on getting USFDA`s approval for ZITUVIMET
Zydus Lifesciences moves up on getting USFDA`s approval for ZITUVIMET
Source: Accord Fintech
2023-11-06 09:38:58 am
Zydus Lifesciences rises on signing co-marketing agreement with Guardant Health Zydus Lifesciences is currently trading at Rs. 577.30, up by 2.00 points or 0.35% from its previous closing of Rs. 575.30 on the BSE. The scrip opened at Rs. 578.30 and has touched a high and low of Rs. 580.65 and Rs. 571.65 respectively. So far 3076 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 390.10 on 22-Nov-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences rises on signing co-marketing agreement with Guardant Health
Zydus Lifesciences rises on signing co-marketing agreement with Guardant Health
Source: Accord Fintech
2023-11-02 11:41:56 am
Zydus Lifesciences moves up as its arm acquires UK based LiqMeds Group Zydus Lifesciences is currently trading at Rs. 574.85, up by 1.05 points or 0.18% from its previous closing of Rs. 573.80 on the BSE. The scrip opened at Rs. 580.60 and has touched a high and low of Rs. 580.60 and Rs. 571.00 respectively. So far 8457 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 390.10 on 22-Nov-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences moves up as its arm acquires UK based LiqMeds Group
Zydus Lifesciences moves up as its arm acquires UK based LiqMeds Group
Source: Accord Fintech
2023-11-01 12:54:12 pm
Zydus Lifesciences surges on signing licensing agreement with Sun Pharma for co-marketing of Desidustat Zydus Lifesciences is currently trading at Rs. 579.85, up by 5.05 points or 0.88% from its previous closing of Rs. 574.80 on the BSE. The scrip opened at Rs. 577.15 and has touched a high and low of Rs. 582.30 and Rs. 574.50 respectively. So far 6464 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 390.10 on 22-Nov-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences surges on signing licensing agreement with Sun Pharma for co-marketing of Desidustat
Zydus Lifesciences surges on signing licensing agreement with Sun Pharma for co-marketing of Desidustat
Source: Accord Fintech
2023-10-30 12:47:16 pm
Zydus Lifesciences shines on getting USFDA`s approval for ZITUVIO tablets Zydus Lifesciences is currently trading at Rs. 581.10, up by 2.55 points or 0.44% from its previous closing of Rs. 578.55 on the BSE.The scrip opened at Rs. 578.60 and has touched a high and low of Rs. 589.15 and Rs. 578.60 respectively. So far 2305 shares were traded on the counter.The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 390.10 on 22-Nov-2022.Last one week high and low of the scrip stood at Rs. 597.30 and Rs...
Zydus Lifesciences shines on getting USFDA`s approval for ZITUVIO tablets
Zydus Lifesciences shines on getting USFDA`s approval for ZITUVIO tablets
Source: Accord Fintech
2023-10-23 10:04:31 am
Zydus Lifesciences rises on getting final nod for Clindamycin Phosphate Gel Zydus Lifesciences is currently trading at Rs. 630.50, up by 6.00 points or 0.96% from its previous closing of Rs. 624.50 on the BSE.The scrip opened at Rs. 628.35 and has touched a high and low of Rs. 630.95 and Rs. 628.15 respectively. So far 1387 shares were traded on the counter.The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 350.30 on 26-Sep-2022.Last one week high and low of the scrip stood at Rs. 653.55 and Rs...
Zydus Lifesciences rises on getting final nod for Clindamycin Phosphate Gel
Zydus Lifesciences rises on getting final nod for Clindamycin Phosphate Gel
Source: Accord Fintech
2023-09-21 09:42:52am
Zydus Lifesciences surges on getting USFDA`s final approval for Norelgestromin and Ethinyl Estradiol Transdermal System Zydus Lifesciences is currently trading at Rs. 643.90, up by 4.20 points or 0.66% from its previous closing of Rs. 639.70 on the BSE.The scrip opened at Rs. 641.80 and has touched a high and low of Rs. 647.30 and Rs. 641.00 respectively. So far 12530 shares were traded on the counter.The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 350.30 on 26-Sep-2022.Last one week high and low of the scrip stood at Rs. 649.40 and R...
Zydus Lifesciences surges on getting USFDA`s final approval for Norelgestromin and Ethinyl Estradiol Transdermal System
Zydus Lifesciences surges on getting USFDA`s final approval for Norelgestromin and Ethinyl Estradiol Transdermal System
Source: Accord Fintech
2023-09-15 03:29:55pm
Zydus Lifesciences inches up in volatile trade Zydus Lifesciences is currently trading at Rs. 628.75, up by 0.05 points or 0.01% from its previous closing of Rs. 628.70 on the BSE.The scrip opened at Rs. 626.45 and has touched a high and low of Rs. 642.85 and Rs. 624.15 respectively. So far 66169 shares were traded on the counter.The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 350.30 on 26-Sep-2022.Last one week high and low of the scrip stood at Rs. 644.20 and R...
Zydus Lifesciences inches up in volatile trade
Zydus Lifesciences inches up in volatile trade
Source: Accord Fintech
2023-09-12 04:02:15pm